Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation

  • 219 Accesses

  • 15 Citations



The aim of the study was to evaluate whether glycosylated granulocyte colony-stimulating factor (G-CSF) (lenograstim) offers a benefit over non-glycosylated G-CSF (filgrastim) in clinically relevant end points after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplantation (PBSCT).


We retrospectively analyzed the outcome of 261 patients treated with either lenograstim (n=68) or filgrastim (n=193). Time to blood cell recovery, toxicities, and infectious complications were analyzed in a total of 469 G-CSF treatment cycles.


Mean time to leukocyte recovery was 10.7 days (SD±0.9) (lenograstim) and 10.8 days (SD±0.6) (filgrastim), respectively. Likewise, time to thrombocyte engraftment, febrile days, duration of therapeutic antibiotic treatment, severity of non-hematological toxicities, duration of in-hospital stay, and duration of G-CSF treatment were similar in both groups. Owing to the physicochemical and pharmacokinetic properties of lenograstim, the required dose until leukocyte recovery was significantly smaller as compared to filgrastim (38.5 vs 54.0 µg/kg of body weight).


Collectively, our data indicate that both G-CSF preparations are equally effective in hastening leukocyte recovery in the setting of high-dose chemotherapy followed by autologous PBSCT.

This is a preview of subscription content, log in to check access.


  1. 1.

    Arakawa T, Prestrelski SJ, Narhi LO, Boone TC, Kenney WC (1993) Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem 12:525–531

  2. 2.

    Baumann I, Testa NG, Lange C, de Wynter E, Luft T, Dexter TM, van Hoef ME, Howell A (1993) Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. Lancet 341:369

  3. 3.

    Bojko P, Scharifi M, Stossel K, Seeber S (2002) Comparison of processing four and five times the patients’ blood volume during peripheral blood stem cell collection and analysis of CD34+38-- and CD34+49d+ subsets during apheresis. J Cancer Res Clin Oncol 128:19–28

  4. 4.

    Bonig H, Silbermann S, Weller S, Kirschke R, Korholz D, Janssen G, Gobel U, Nurnberger W (2001) Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study. Bone Marrow Transplant 28:259–264

  5. 5.

    Carter CR, Whitmore KM, Thorpe R (2004) The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol 75:512–522

  6. 6.

    Clogston CL, Hu S, Boone TC, Lu HS (1993) Glycosidase digestion, electrophoresis and chromatographic analysis of recombinant human granulocyte colony-stimulating factor glycoforms produced in Chinese hamster ovary cells. J Chromatogr 637:55–62

  7. 7.

    Common Terminology Criteria for Adverse Events. Cancer Therapy Evaluation Program (2003), Version 3.0. (http://ctep.cancer.gov/reporting/ctc.html)

  8. 8.

    Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074–2081

  9. 9.

    Esser M, Brunner H (2003) Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 21:1295–1313

  10. 10.

    Gisselbrecht C, Prentice HG, Bacigalupo A, Biron P, Milpied N, Rubie H, Cunningham D, Legros M, Pico JL, Linch DC (1994) Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343:696–700

  11. 11.

    Hoglund M, Smedmyr B, Simonsson B, Totterman T, Bengtsson M (1996) Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 18:19–27

  12. 12.

    Kim IH, Park SK, Suh OK, Oh JM (2003) Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin 19:753–759

  13. 13.

    Kubota N, Orita T, Hattori K, Oh-eda M, Ochi N, Yamazaki T (1990) Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 107:486–492

  14. 14.

    Mire-Sluis AR, Das RG, Thorpe R (1995) The international standard for granulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. Participants of the Collaborative Study. J Immunol Methods 179:117–126

  15. 15.

    Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R (1988) Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1:667–672

  16. 16.

    Nissen C (1994) Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 30A [Suppl 3]:S12–S14

  17. 17.

    Nohynek GJ, Plard JP, Wells MY, Zerial A, Roquet F (1997) Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Cancer Chemother Pharmacol 39:259–266

  18. 18.

    Oh-Eda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima T, Orita T, Tomonou K, Yamazaki T, Ochi N (1990) O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 265:11432–11435

  19. 19.

    Pedrazzoli P, Gibelli N, Pavesi L, Preti P, Piolini M, Bertolini F, Robustelli della CG (1996) Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 16:1781–1785

  20. 20.

    Querol S, Cancelas JA, Amat L, Capmany G, Garcia J (1999) Effect of glycosylation of recombinant human granulocytic colony-stimulating factor on expansion cultures of umbilical cord blood CD34+ cells. Haematologica 84:493–498

  21. 21.

    Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM (1989) Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891–895

  22. 22.

    Tanaka H, Tanaka Y, Shinagawa K, Yamagishi Y, Ohtaki K, Asano K (1997) Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 9:360–369

  23. 23.

    Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC (1997) Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 98:474–479

  24. 24.

    Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907–1929

  25. 25.

    Zsebo KM, Cohen AM, Murdock DC, Boone TC, Inoue H, Chazin VR, Hines D, Souza LM (1986) Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 172:175–184

Download references

Author information

Correspondence to A. Hüttmann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hüttmann, A., Schirsafi, K., Seeber, S. et al. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 131, 152–156 (2005). https://doi.org/10.1007/s00432-004-0636-x

Download citation


  • lenograstim
  • filgrastim
  • HDC